Damage-associated molecular patterns and immunogenic cancer cell death in cancer immunotherapy

My research is focused on cancer immunology and immunotherapy (e.g. anticancer vaccines, immunogenic cell death, immune effector responses), photodynamic therapy, combinatorial therapies involving chemo-(radio-)therapy and novel immunostimulatory factors (e.g. damage-associated molecular patterns/DAMPs, chemokines and cytokines). I have (and continue to) delineated novel cancer signalling (e.g. danger signalling, immunogenic signalling, cross-talk between ER stress-autophagy-caspases in cancer) or therapy-relevant mechanisms (e.g. immunogenic phagocytosis, general anti-cancer immunosurveillance) operating at the interface between (stressed or dying) cancer cells and host immune cells (like dendritic cells, neutrophils, NK cells and Th1, Th17, Treg or cytotoxic T cells). I also work on translation of anticancer immunotherapy, novel drug discovery strategies  and discovery of prognostic and predictive cancer biomarkers.

Keywords:cancer

Disciplines:Morphological sciences, Oncology